As co-founder and President of Advera Health Analytics, Brian oversees the company’s growth strategy. Prior to Advera Health Analytics, Brian was a co-founder of Sagient Research Systems Inc. He served as the company's president and CEO from 1999 to 2009 and as the chairman of the board from 2010 until the company's acquisition in May 2012 by Informa plc. Sagient Research Systems is a publisher of specialized research and data. They develop, produce, and sell proprietary research products to global enterprises, including pharmaceutical companies, investment banks, mutual and hedge funds, academic institutions, and government agencies.
Jim brings over 12 years of experience in commercial strategy, global sales management and execution, business development, and product development. He has over 9 years of specific domain expertise in biopharma market research, intelligence, and data. Prior to joining Advera Health, Jim served as the Global Head of Sales for the BioPharm Solutions Suite at Infinata, Inc. (A part of The Mergermarket Group, a Financial Times Group company and a division of Pearson, Plc.).
As co-founder and Chief Product Officer of Advera Health Analytics, Inc., Bob Kyle is in charge of defining and driving the company’s product strategy and managing the product life cycle, from conception through launch. Bob’s product vision drives and inspires the company to continually innovate and rapidly adapt products to the changing needs of the marketplace. Executing consistently and effectively on product refinements and new releases ensures that AdverseEvent’s growth strategy is intertwined with that of its clients.
Keith has 17 years of science, business, and intellectual property development experience in the biotechnology, pharmaceutical, and consumer goods industries. Prior to Advera Health, he was the CBO of Antigen Discovery, COO of ChemoTherapeutics, COO of LALO Tactical, COO of Thuris Corporation, and Head of Scientific Affairs at Ancile Pharmaceuticals. Keith has a PhD in Neuropharmacology from the laboratory of Gary Lynch and an undergraduate degree in biology, both from UC Irvine.
Sharon has deep experience in creating, marketing, and running consumer-facing companies. She has held senior marketing and operational positions at Kaplan (A Washington Post Company), NBC and The News Corporation. Prior to those she held senior positions within several marketing communications firms and has been the recipient of numerous product, marketing and public relations industry awards.
The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule in May aimed at improving the quality and performance of Medicaid managed care organizations (MCOs).
It seeks to “modernize the Medicaid managed care regulations to reflect changes in the usage of managed care delivery systems.” Simply, the goal is to align with existing commercial, Marketplace, and Medicare Advantage regulations in order to improve the quality of care. CMS must look for ways to use available data to help Medicaid MCOs drive significant improvements in patient care and lower overall costs. Incorporating analysis of data that can help reduce of preventable events affecting outcomes and costs, including analysis of adverse drug events, as part of CMS’ overall quality strategy is one way to modernize and affect positive change.
We submitted a letter providing comments on the proposed rule, including recommended changes to strengthen the Medicaid drug benefit within managed care programs. To view our comment letter on the proposed rule, click the link below.
If you agree it’s time to take action to improve patient safety and lower healthcare costs, let your voice be heard! There are two ways you can get involved:
1. Write to your elected officials in Congress (download a template email letter here), urging them to ask CMS to make evaluation of adverse drug event data a requirement for drug coverage decisions made by Medicaid and Medicare prescription drug plans. You can search, and find contact information, for your Senators/Representatives here.
Dr. Bunney is the Distinguished Professor of Psychiatry and Human Behavior and the Della Martin Chair of Psychiatry at UCI. His major research interests involve clinical psychobiological studies of manic-depressive illness, and schizophrenia. These include behavioral studies, studies of the efficacy and mode of action of pharmacological agents, brain imaging, genetic studies utilizing and investigations of brain circuitry abnormalities which may be related to the major psychoses.
Dr. Doraiswamy is a professor in Psychiatry and Medicine at Duke University Medical Center and a leading expert in psychopharmacology, drug safety and clinical trials. He has coauthored more than 200 scientific articles and served as an advisor to the WHO, FDA, NIH, pharmaceutical companies and leading advocacy groups.
Dr. Fiore is president of SSI Strategy, which provided pharmaceutical management and pharmacovigilance consulting. Prior to SSI, Dr. Fiore was the Chief Medical Officer of The Medicines Company, a global pharmaceutical company focused on advancing the treatment of critical care patients. Dr. Fiore also held senior positions at Merck, Abbott Laboratories, and McKinsey Consulting.
Dr. Harrington is the new Chair of the Department of Medicine at Stanford University School of Medicine, effective July 2012. Prior to joining Stanford, Dr. Harrington was the director of the Duke Clinical Research institute, the largest academic clinical research organization in the world with a faculty of over 200 and a professional staff of over 1,100 that represents every major therapeutic area in medicine. Dr. Harrington’s research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of clinical trials.
Dr. Nicholas Tatonetti trained in mathematics and molecular biology at Arizona State University before receiving his PhD in biomedical informatics in 2012 from Stanford University. His dissertation was focused on the development of novel statistical and computational methods for observational data mining. He applied these methods to drug safety surveillance where he discovered and validated new drug effects and interactions. In September 2012, Dr. Tatonetti joined the faculty as an Assistant Professor in the Departments of Biomedical Informatics, Systems Biology, and Medicine. Shortly after, he became Director for the Clinical Informatics Shared Resource (CISR) at the Herbert Irving Comprehensive Cancer Center. His lab at Columbia is focused on expanding upon his previous work in detecting, explaining, and validating drug effects and drug interactions from large-scale observational data.
Widely published in both clinical and bioinformatics, Dr. Tatonetti is passionate about the integration of hospital data (stored in the electronic health records) and high-dimensional biological data (captured using next-generation sequencing, high-throughput screening, and other "omics" technologies). His lab develops the algorithms, techniques, and methods for analyzing enormous and diverse data by designing rigorous computational and mathematical approaches that address the fundamental challenges of observational analysis -- bias and confounding. Foremost, they integrate medical observations with systems and chemical biology models to, not only, explain clinical effects, but also further our understanding basic biology and human disease. Dr. Tatonetti has been featured by the New York Times, Genome Web, and Science Careers. His work has been picked up by the mainstream and scientific media and generated hundreds of news articles.